The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials

被引：52

作者：

Hasegawa, Yoshikazu ^{[1
]}

Ando, Masahiko ^{[2
]}

Maemondo, Makoto ^{[3
]}

Yamamoto, Satomi ^{[4
]}

Isa, Shun-ichi ^{[5
]}

Saka, Hideo ^{[6
]}

Kubo, Akihito ^{[7
]}

Kawaguchi, Tomoya ^{[8
]}

Takada, Minoru ^{[9
]}

Rosell, Rafael ^{[10
]}

Kurata, Takayasu ^{[11
]}

Ou, Sai-Hong Ignatius ^{[12
]}

机构：

[1] Izumi Municipal Hosp, Osaka, Japan

[2] Nagoya Univ Hosp, Nagoya, Aichi, Japan

[3] Miyagi Canc Ctr, Natori, Miyagi, Japan

[4] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[5] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Osaka, Japan

[6] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan

[7] Aichi Med Univ, Sch Med, Nagoya, Aichi, Japan

[8] Osaka City Univ, Grad Sch Med, Osaka 558, Japan

[9] Koyo Hosp, Wakayama, Japan

[10] Catalan Inst Oncol, Barcelona, Spain

[11] Kansai Med Univ, Hirakata Hosp, Osaka, Japan

[12] Univ Calif Irvine, Sch Med, Chao Family Comprehens Canc Ctr, Orange, CA 92868 USA

来源：

ONCOLOGIST | 2015年 / 20卷 / 03期

关键词：

Meta-analysis; EGFR TKIs; Smoking status; EGFR mutant non-small cell lung cancer; Gefitinib; Erlotinib; Afatinib; OPEN-LABEL; CARBOPLATIN-PACLITAXEL; INCREASED SENSITIVITY; ASIAN PATIENTS; PHASE-III; ADENOCARCINOMA; GEFITINIB; ERLOTINIB; MULTICENTER; GEMCITABINE;

D O I：

10.1634/theoncologist.2014-0285

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. Univariate analyses from several randomized phase III trials seemed to suggest ever-smokers with advanced mutated epidermal growth factor receptor (EGFRm) non-small cell lung cancer (NSCLC) did not seem to benefit from EGFR tyrosine kinase inhibitors (TKIs) as first-line treatment when compared with platinum-doublet chemotherapy as measured by progression-free survival (PFS). Methods. A literature-based meta-analysis of PFS outcomes as measured by log-transformed pooled hazard ratio (HR) was performed using a random-effect model. Pooled HRs for smoking status, age, gender, ethnicity, type of EGFR mutation, and EGFR TKI were obtained. Comparison of the pooled HR was performed by metaregression analysis. Results. Among the 1,649 EGFRm NSCLC patients analyzed from 7 prospective randomized trials (WJTOG3405, NEJ002, EURTAC, OPTIMAL, LUX Lung-3, LUX Lung-6, and ENSURE), 83.7% were Asians, and 30.0% were ever-smokers. An equal percentage of ever-smokers received doublet chemotherapy (30.2%) or EGFR TKI (30.0%). The pooled HR for PFS was 0.29 (95% confidence interval [CI]: 0.21-0.39) for never-smokers and 0.54 (95% CI: 0.38-0.76) for ever-smokers (p < .007 by metaregression). The pooled PFS HR for exon 19 deletion was 0.25 (95% CI: 0.19-0.31) and 0.44 for exon 21 substitution (95% CI: 0.34-0.57) (p < .001 by metaregression analysis). The pooled PFS HR was 0.33 (95% CI: 0.24-0.46) for Asians and 0.48 for non-Asians (95% CI: 0.28-0.84) (p = .261 by metaregression analysis). Conclusion. EGFRm NSCLC patients derived significant PFS benefit from TKI over platinum-doublet chemotherapy as first-line treatment regardless of smoking status; however, PFS benefit is significantly better in never-smokers by metaregression analysis.

引用

页码：307 / 315

页数：9

共 27 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib [J].

Carey, Kendall D. ;

Garton, Andrew J. ;

Romero, Maria S. ;

Kahler, Jennifer ;

Thomson, Stuart ;

Ross, Sarajane ;

Park, Frances ;

Haley, John D. ;

Gibson, Neil ;

Sliwkowski, Mark X. .

CANCER RESEARCH, 2006, 66 (16) :8163-8171

[3] Src Mediates Cigarette Smoke-Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells [J].

Filosto, Simone ;

Baston, David S. ;

Chung, Samuel ;

Becker, Cathleen R. ;

Goldkorn, Tzipora .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (08) :1579-1590

[4] Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers [J].

Govindan, Ramaswamy ;

Ding, Li ;

Griffith, Malachi ;

Subramanian, Janakiraman ;

Dees, Nathan D. ;

Kanchi, Krishna L. ;

Maher, Christopher A. ;

Fulton, Robert ;

Fulton, Lucinda ;

Wallis, John ;

Chen, Ken ;

Walker, Jason ;

McDonald, Sandra ;

Bose, Ron ;

Ornitz, David ;

Xiong, Donghai ;

You, Ming ;

Dooling, David J. ;

Watson, Mark ;

Mardis, Elaine R. ;

Wilson, Richard K. .

CELL, 2012, 150 (06) :1121-1134

[5] Effects of smoking on the pharmacokinetics of erlotinib [J].

Hamilton, M ;

Wolf, JL ;

Rusk, J ;

Beard, SE ;

Clark, GM ;

Witt, K ;

Cagnoni, PJ .

CLINICAL CANCER RESEARCH, 2006, 12 (07) :2166-2171

[6] First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung [J].

Han, Ji-Youn ;

Park, Keunchil ;

Kim, Sang-We ;

Lee, Dae Ho ;

Kim, Hyae Young ;

Kim, Heung Tae ;

Ahn, Myung Ju ;

Yun, Tak ;

Ahn, Jin Seok ;

Suh, Cheolwon ;

Lee, Jung-Shin ;

Yoon, Sung Jin ;

Han, Jong Hee ;

Lee, Jae Won ;

Jo, Sook Jung ;

Lee, Jin Soo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1122-1128

[7] Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers [J].

Hughes, Andrew N. ;

O'Brien, Mary E. R. ;

Petty, W. Jeffrey ;

Chick, Jonathan B. ;

Rankin, Elaine ;

Woll, Penella J. ;

Dunlop, David ;

Nicolson, Marianne ;

Boinpally, Ramesh ;

Wolf, Julie ;

Price, Allan .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1220-1226

[8] Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing [J].

Imielinski, Marcin ;

Berger, Alice H. ;

Hammerman, Peter S. ;

Hernandez, Bryan ;

Pugh, Trevor J. ;

Hodis, Eran ;

Cho, Jeonghee ;

Suh, James ;

Capelletti, Marzia ;

Sivachenko, Andrey ;

Sougnez, Carrie ;

Auclair, Daniel ;

Lawrence, Michael S. ;

Stojanov, Petar ;

Cibulskis, Kristian ;

Choi, Kyusam ;

de Waal, Luc ;

Sharifnia, Tanaz ;

Brooks, Angela ;

Greulich, Heidi ;

Banerji, Shantanu ;

Zander, Thomas ;

Seidel, Danila ;

Leenders, Frauke ;

Ansen, Sascha ;

Ludwig, Corinna ;

Engel-Riedel, Walburga ;

Stoelben, Erich ;

Wolf, Juergen ;

Goparju, Chandra ;

Thompson, Kristin ;

Winckler, Wendy ;

Kwiatkowski, David ;

Johnson, Bruce E. ;

Jaenne, Pasi A. ;

Miller, Vincent A. ;

Pao, William ;

Travis, William D. ;

Pass, Harvey I. ;

Gabriel, Stacey B. ;

Lander, Eric S. ;

Thomas, Roman K. ;

Garraway, Levi A. ;

Getz, Gad ;

Meyerson, Matthew .

CELL, 2012, 150 (06) :1107-1120

[9] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J].

Inoue, A. ;

Kobayashi, K. ;

Maemondo, M. ;

Sugawara, S. ;

Oizumi, S. ;

Isobe, H. ;

Gemma, A. ;

Harada, M. ;

Yoshizawa, H. ;

Kinoshita, I. ;

Fujita, Y. ;

Okinaga, S. ;

Hirano, H. ;

Yoshimori, K. ;

Harada, T. ;

Saijo, Y. ;

Hagiwara, K. ;

Morita, S. ;

Nukiwa, T. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :54-59

[10] Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib [J].

Jackman, David M. ;

Yeap, Beow Y. ;

Sequist, Lecia V. ;

Lindeman, Neal ;

Holmes, Alison J. ;

Joshi, Victoria A. ;

Bell, Daphne W. ;

Huberman, Mark S. ;

Halmos, Balazs ;

Rabin, Michael S. ;

Haber, Daniel A. ;

Lynch, Thomas J. ;

Meyerson, Matthew ;

Johnson, Bruce E. ;

Jaenne, Pasi A. .

CLINICAL CANCER RESEARCH, 2006, 12 (13) :3908-3914

← 1 2 3 →